3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Non-metastatic Castration-resistant Prostate Cancer
4
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Urogenital Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Non-metastatic Prostate Cancer
1
Metastatic Hormone-sensitive Prostate Cancer
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Prostate Carcinoma
1
Interventions
enzalutamide
1
darolutamide
1
apalutamide
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Metastatic Hormone-sensitive Prostate Cancer
×
darolutamide
×
Clear all
NCT06498921
2024-10-24
BELBEQA
Bayer
Completed
106 enrolled